Navigation Links
Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
Date:5/19/2011

e TTR build up in their peripheral nerves and experience the loss of motor functions, such as walking.  Although these patients experience debilitating nerve damage throughout their body, they typically die from wasting due to the accumulation of TTR in the intestinal tract, which prevents the proper absorption of nutrients.  Currently there are no approved drugs to treat transthyretin amyloidosis, and the only approved available option is liver transplant.  Unfortunately, availability of donor livers is very limited and only a fraction of patients are eligible for this very expensive and invasive procedure.  

In March 2010, Isis entered into a strategic alliance with GSK to develop RNA therapeutics for rare and infectious diseases.  Under the terms of the agreement, Isis received an upfront $35 million payment from GSK and is eligible to receive license fees and milestone payments, totaling nearly $1.5 billion, in the event all six programs are successfully developed for one or more indications and commercialized through to pre-agreed sales targets.  With the initiation of the Phase 1 study of ISIS-TTRRx, Isis has earned $10 million in milestone payments under the collaboration.

ABOUT ISIS-TTRRx

Transthyretin amyloidosis is a genetic disease in which the patient inherits a mutant gene that produces a misfolded form of TTR, which progressively accumulates in tissues, impairing their function.  In patients with transthyretin amyloidosis, both the mutant and normal forms of TTR can build up as fibrils in tissues, including heart, peripheral nerves, and the gastrointestinal tract.  The presence of fibrils interferes with the normal functions of these tissues, and as the fibril deposits enlarge more tissue damage occurs and the disease worsens.  There are two common types of transthyretin amyloidosis, familial amyloid cardiomyopathy, or FAC, which affects more than 40,000 patients worldwide, and F
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
2. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
3. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
4. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
5. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
6. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
7. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
8. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
9. SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
10. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
11. Trinity Biotech Investor Group Initiates Campaign of ADR Conversion to Force a Special Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... MENLO PARK, Calif. , Aug. 27, 2015 /PRNewswire/ ... company in the emerging field of regenerative medicine, today ... two investor conferences in the month of September.  ... Officer, will present at Rodman & Renshaw,s 17th Annual ... 10:25am ET/7:25am PT at the St. Regis Hotel in ...
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER TOLEDO's ... narrows down the product choices to a manageable shortlist of bench and floor ... to models that fit best with the customer’s industry and application. , ...
(Date:8/26/2015)... Aug. 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... advanced testing solutions for the detection of foodborne pathogens, ... at the Sidoti & Company Emerging Growth Conference on ... held at the New York Marriott Marquis. ... available through the investor relations section of Roka Bioscience,s ...
(Date:8/26/2015)... and BEIJING , August 26, 2015 ... Scene with Impressive Acheivements  DiaCardio wins 1 st ... The competition, led in Israel ... featured 21 startups from countries including the US, China ... and Latin America .  Impressive ...
Breaking Biology Technology:Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2METTLER TOLEDO Updates Online Scale Selection Tool 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6
... PharmaTech (NYSE:,WX), a leading pharmaceutical, biotechnology and medical ... China and the United,States, today announced that it ... of Strategy., (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ), ... worked at Pfizer Inc., where,she co-led Pfizer,s venture ...
... Free access to 'Best Practices for Long-term ... R. Rajagopal's highly successful November 2007 position ... Option', is being offered. It emphasizes the ... as it nears commercialization as a viable ...
... July 10 Pinnacle Biologics, a,private, full-service pharmaceutical ... into an agreement with pharmexx to expand sales,support ... Europe. Terms of the,agreement were not disclosed., ... "We are,pleased to conclude this agreement with pharmexx, ...
Cached Biology Technology:WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy 2Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 2Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 3Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 4Pinnacle Biologics Announces Agreement With pharmexx to Expand Sales Support Activities in Key European Markets 2
(Date:8/26/2015)... 26, 2015 The report "Multi-Factor Authentication ... Factor), Application (Travel & Immigration, Government, Banking, Defense, Commercial ... to 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is ... at a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ...
(Date:8/20/2015)... The wearable technology market has traditionally ... healthy. However, wearable technology has the potential to ... improve diagnostic capabilities and therapeutic outcomes. Today, Leaf ... Technologies Conference 2015 , where Barrett Larson ... healthcare.    "Over the past decade, ...
(Date:8/18/2015)... 2015  Navitas today announced that it ... Submission Content Management webinar scheduled on August ... to the Implementation of Regulatory Submission Standards ... industry, vendors, health authorities, consultants and the ... a standard method of implementing electronic submission ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... May 28, 2008 Oslo SEVEN pioneering scientists ... nanoscience, neuroscience and astrophysics have become the first recipients ... selected for their groundbreaking research that has significantly advanced ... an ultra-small scale, the basic circuitry of the human ...
... a contract signed today, the European Commission has ... decide upon the best way to unite Europes ... network for the life sciences. The European Life-science ... by the European Molecular Biology Laboratorys European Bioinformatics ...
... is available in Spanish . , ... suffering cardiovascular diseases. For her doctoral thesis, University of ... the effects of substitute treatments and the genetic factors ... is a natural period in the ageing process of ...
Cached Biology News:Names of inaugural Kavli Prize winners revealed 2Names of inaugural Kavli Prize winners revealed 3Securing the future of Europe's biological data resources 2Quest for better treatment for effects of menopause 2Quest for better treatment for effects of menopause 3
... a cocktail of 3 siRNAs specifically targeted ... most popular product. The siTrio reagent guarantees ... your target gene when used under standard ... confirmation of optimal transfection with one of ...
... A multi-purpose, high gel-strength agarose suitable for ... from conventional constant field to Pulsed Field ... gel strength and exclusion limits, Multi ABgarose ... reduced running times. This in turn means ...
... molecular screening, low melting point agarose where ... is recommended for separation of nucleic acids ... PCR products. Micro ABgarose is also suited ... for blotting techniques. At a 3% concentration, ...
Sheep polyclonal to Salmonella Shoreditch ( Abpromise for all tested applications). Antigen: Native Salmonella shoreditch (Group D2)....
Biology Products: